FDA vs EU MDR: Regulatory Comparison for Dual Market Access
Understanding FDA vs EU MDR requirements is essential for medical device manufacturers targeting both the U.S. and European markets. Although both systems focus on safety and performance, FDA vs EU MDR regulations differ in classification, clinical expectations, documentation, timelines, and compliance burden. These FDA vs EU MDR differences often increase costs, extend approval timelines, and require separate regulatory strategies.
Key FDA vs EU MDR Differences
Regulatory Framework
- FDA: Rule-based system under 21 CFR Part 820
- EU MDR: Risk-based, principle-driven regulation
Device Classification
- FDA: Class I, II, III
- EU MDR: Class I, IIa, IIb, III
- Same device may face stricter classification under EU MDR
Clinical Data Requirements
- FDA: 510(k) pathway allows substantial equivalence
- EU MDR: Requires stronger clinical evidence and evaluation
Post-Market Surveillance
- FDA: Reactive, event-based reporting
- EU MDR: Proactive PMS, PMCF, and periodic reports mandatory
Approval Process
- FDA: Centralized review
- EU MDR: Notified Body involvement with longer timelines
Documentation
- FDA: Submission-based format (510(k), PMA, De Novo)
- EU MDR: Detailed Technical Documentation (Annex II & III, GSPR)
Costs & Timelines
- FDA: More predictable fees and faster review
- EU MDR: Higher compliance costs and longer review cycles
Successfully managing FDA vs EU MDR compliance requires a well-aligned quality system, expanded technical documentation, and a clear regulatory roadmap to avoid delays and dual compliance challenges.